Human homozygous type I plasminogen deficiency and ligneous conjunctivitis
Corresponding Author
ANNE-MARIE MINGERS
Children's Hospital of the University of Würzburg, Würzburg, Germany
Am Hölzlein 20, D-97076 Würzburg, Germany.Search for more papers by this authorANTON PHILAPITSCH
Hyland-Immuno Division, Baxter Healthcare, Vienna, Austria
Search for more papers by this authorPETRA ZEITLER
Children's Hospital of the University of Würzburg, Würzburg, Germany
Search for more papers by this authorVOLKER SCHUSTER
Children's Hospital of the University of Würzburg, Würzburg, Germany
Search for more papers by this authorHANS PETER SCHWARZ
Hyland-Immuno Division, Baxter Healthcare, Vienna, Austria
Search for more papers by this authorHANS WOLFGANG KRETH
Children's Hospital of the University of Würzburg, Würzburg, Germany
Search for more papers by this authorCorresponding Author
ANNE-MARIE MINGERS
Children's Hospital of the University of Würzburg, Würzburg, Germany
Am Hölzlein 20, D-97076 Würzburg, Germany.Search for more papers by this authorANTON PHILAPITSCH
Hyland-Immuno Division, Baxter Healthcare, Vienna, Austria
Search for more papers by this authorPETRA ZEITLER
Children's Hospital of the University of Würzburg, Würzburg, Germany
Search for more papers by this authorVOLKER SCHUSTER
Children's Hospital of the University of Würzburg, Würzburg, Germany
Search for more papers by this authorHANS PETER SCHWARZ
Hyland-Immuno Division, Baxter Healthcare, Vienna, Austria
Search for more papers by this authorHANS WOLFGANG KRETH
Children's Hospital of the University of Würzburg, Würzburg, Germany
Search for more papers by this authorAbstract
On the basis of a questionnaire sent to the ophthalmology departments of hospitals throughout Germany, 10 patients with ligneous conjunctivitis or pseudomembranous disease, ranging in age from 1 to 71 years were identified. All 10 patients had severely reduced plasminogen levels. Genetic analysis revealed homozygous type I plasminogen deficiency (which had not previously been described in humans) in 7 patients and compound heterozygous plasminogen deficiency in 1 patient. Clear differentiation was not possible in 2 patients. Most of the parents had heterozygous plasminogen deficiency. None of the patients had experienced any episodes of thrombosis. Additionally, the following observations were made: 1) Levels of polymorphonuclear (PMN)-elastase protein were markedly elevated in 6 of 6 patients and 10 of 11 parents tested, and levels were higher in homozygotes than in heterozygotes. 2) Hereditary factor XII deficiency was found in 3 of 6 patients tested. 3) Cl-inhibitor was elevated in 2 of 4 patients, prekallikrein was elevated in 1 of 4 patients, and plasminogen activator inhibitor type 1 was elevated in 1 of 4 patients. Infusions of lys-plasminogen concentrate induced pronounced fibrinolytic activity as indicated by high levels of D-dimer, increases in plasmin-antiplasmin complex and decreases in polymorphonuclear elastase. Cl-inhibitor, prekallikrein and PAI-1 normalized after repeated infusions of lys-plasminogen. In contrast to dysplasminogenemia, severe type I plasminogen deficiency might be seen as a problem of extravascular space, in particular of the mucous membranes, possibly triggered by mechanically induced or inflammatory lesions of the vessels supplying the tissue.
REFERENCES
- 1 Mingers AM, Heimburger N., Lutz E.. Familiärer homozygoter und heterozygoter Typ I-Plasminogenmangel. In: I. Scharrer, W. Schramm, editors. 25. Hämophilie-Symposium 1994. Springer, Berlin , 1995; 96–104.
- 2 Mingers AM, Heimburger N., Lutz E., Seeger J.. Homozygous and heterozygous plasminogen type I deficiencies combined with ligneous conjunctivitis in three unrelated families. Turk J Haematol, 1995; 14: abstract 58.
- 3 Mingers AM, Heimburger N., Lutz E.. Gerinnungsbefunde vor und nach Lys-Plasminogen-Infusion bei homozygotem Typ I Plasminogenmangel. Infusionstherapie Transfusionsmedizin, 1995; 22 (Suppl 22): 16.
- 4 Mingers AM, Heimburger N., Zeitler P., Kreth HW, Schuster V.. Homozygous type I plasminogen deficiency. Semin Thromb Hemostas, 1997; 23: 259–69.
- 5 Berlin AJ, Carim M., Langston RH, Price RL. Scleral grafting in the management of ligneous conjunctivitis. Ophthalmic Surg, 1982; 13: 288–91.
- 6 Nover A., Knieper P.. Die Conjunctivitis lignosa, eine noch immer ungeklärte Erkrankung. Klin Monatsbl Augenheilkd, 1982; 181: 338–40.
- 7 Melikan HE. Treatment of ligneous conjunctivitis. Ann Ophthalmol, 1985; 17: 763–5.
- 8 Bateman JB, Pettit TH, Isenberg SJ, Simons KB. Ligneous conjunctivitis: An autosomal recessive disorder. J Pediatr Ophthalmol Strabismus, 1986; 23: 137–40.
- 9 Eagle RC, Brooks JSJ, Katowitz JA, Weinberg JC, Perry HD. Fibrin as a major constituent of ligneous conjunctivitis. Am J Ophthalmol, 1986; 101: 493–4.
- 10 Hidayat AA, Riddle PJ. Ligneous conjunctivitis: A clinicopathologic study of 17 cases. Ophthalmology, 1987; 94: 949–59.
- 11 Pfannkuch F., Schmidt R., Schmidt B., Seiler Th. Morphologische Untersuchungen zur Pathogenese der Conjunctivitis lignosa. Klin Monatsbl Augenheilkd, 1987; 190: 40–5.
- 12 Cohen TD, Cruysberg JR, Deutman AF, Manschot WA. Ligneous conjunctivitis. Doc Ophthalmol, 1989; 64: 5–11.
- 13 Rubin A., Buck D., MacDonald MR. Ligneous conjunctivitis involving the cervix. Case report. Br J Obstet Gynaecol, 1989; 96: 1228–30.
- 14 Cohen SR. Ligneous conjunctivitis: An ophthalmic disease with potentially fatal tracheobronchial obstruction. Laryngeal and tracheobronchial features. Ann Otol Rhinol Laryngol, 1990; 99: 509–12.
- 15 Nüssgens Z., Roggenkämper P.. Ligneous conjunctivitis. Ten years follow up. Ophthalmic paediatr Genet, 1993; 14: 137–40.
- 16 Parunovic A., Stefanovic D.. Conjunctivitis lignosa and hydrocephalus (an unusual association of 2 diseases). Vestn Oftalmol 1993; 109: 30–1.
- 17 Scurry J., Planner R., Fortune DW, Lee CS, Rode J.. Ligneous (pseudomembranous) inflammation of the female genital tract. A report of two cases. J Reprod Med, 1993; 38: 407–12.
- 18
Robbins KC,
Summaria L..
Human plasminogen and plasmin.
Meth Enzymol, 1970; 19: 184–99.
10.1016/0076-6879(70)19013-6 Google Scholar
- 19 Freitag HJ, Bäcker VU, Thie A., Tilsner V., Philapitsch A., Schwarz HP, Webhof U., Müller A., Zeumer H.. Lys-Plasminogen as an adjunct to local intra-arterial fibrinolysis for carotid territory stroke: laboratory and clinical findings. Neuroradiologie, 1996; 38: 181–5.
- 20 Shapiro A., Abe T., Aledort LM, et al. Low risk of vapor-heated factor VII concentrate or factor IX complex in first-time recipients of blood components. Transfusion, 1995; 35: 204–8.
- 21
Schuster V.,
Mingers AM,
Zeitler P.,
Kreth HW.
Homozygous type I plasminogen deficiency as a cause of ligneous conjunctivitis. Laboratory and molecular studies in 4 unrelated Turkish girls.
Pediatr Res, 1997; 41: 784.
10.1203/00006450-199705000-00201 Google Scholar
- 22 Schuster V., Mingers AM, Seidenspinner S., Nüssgens Z., Pukrop T., Kreth HW. Homozygous mutations in the plasminogen gene of two unrelated girls with ligneous conjunctivitis. Blood, 1997; 90: 958–66.
- 23 Mingers AM, Zeitler-Zapf P.. Pathologic values for aPTT and Quick during childhood. Ann Hematol, 1994; 68: abstract 54.
- 24 Plow EF. Leukocyte elastase release during blood coagulation. J Clin Invest, 1982; 69: 564–72.
- 25 Jochum M., Machleidt W., Fritz H.. Proteolytic enzyme system. In: G. Schlag, H. Redl, editors. Pathology of Shock, Sepsis, and Organ Failure. Springer, Berlin 1993; 532–48.
- 26
Jochum M.,
Machleidt W.,
Neuhof H.,
Fritz H..
Proteinasen. In: G. Schlag,
H. Redl, editors.
Pathology of Shock, Sepsis, and Organ Failure. Springer,
Berlin
1993; 46–60.
10.1007/978-3-642-76736-4_5 Google Scholar
- 27 Jochum M.. Leukozytenproteinasen und Zytokine bei akuten Entzündungen. In: UT Hopt, M. Büsing, HD Becker, editors. Akute Pankreatitis-Transplantatpankreatitis. Karger, Basel 1994; 82–93.
- 28 Heiden M., Seitz E., Egbring R.. The role of inflammatory cells and their proteases in extravascular fibrinolysis. Semin Thromb Hemostas, 1996; 22: 497–501.
- 29 Bach-Gansmo ET, Halvorsen S., Godal HC, Skjonsberg OH. D-dimers are degraded by human neutrophil elastase. Thromb Res, 1996; 82: 177–86.
- 30 Lijinen HR, Carmeliet P., Bouché A., Mons L., Ploplis VA, Plow EF, Collen D.. Restoration of thrombolytic potential in plasminogen-deficient mice by bolus administration of plasminogen. Blood, 1996; 88: 870–6.
- 31 Ploplis VA, Carmeliet P., Vazirzadeh S., Van Vlaenderen J., Mons L., Plow EF, Collen D.. Effects of disruption of the plasminogen gene on thrombosis, growth and health in mice. Circulation, 1995; 92: 2585–93.
- 32 Carmeliet P., Schoongans L., Kieckens L., Ream B., Degen J., Bronson R., De Vos R., Van den Oord JJ, Collen D., Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature, 1994; 368: 419–24.
- 33 Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes and Development, 1995; 9: 794–807.
- 34 Werb Z., Alexander CM. Proteinases and matrix degeneration. In: WN Kelly, ED Harris, S. Ruddy, CB Sledge, editors. Textbook of Rheumatology, 4th ed vol 1, Saunders, Philadelphia , 1993; 248–68.
- 35 Kramer MD, Reinartz J., Brunner G., Schirrmacher V.. Plasmin in pericellular proteolysis and cellular invasion. Invasion Metastasis, 19941995; 14: 210–22.
- 36 Arend WP, Dayer JM. Cytokines and growth factors. In: WN Kelley, ED Harris, S. Ruddy, CB Sledge, editors. Textbook of Rheumatology, 4th ed vol 1, Saunders, Philadelphia , 1993; 227–44.
- 37 Kramer MD, Schäfer B., Reinartz J.. Plasminogen activation by human keratinocytes: Molecular pathways and cell-biological consequences. Biol Chem Hoppe-Seyler, 1995; 376: 131–41.
- 38 Schäfer B., Maier K., Eickhoff U., Todd RF, Kramer MD. Plasminogen activation in healing wounds. Am J Pathol, 1994; 144: 1269–80.
- 39 Heimburger N., Stief TW, Römisch J.. Entzündungsreaktionen und Hämostase: Wechselwirkungen. In: V. Tilsner FR Matthias, editors. Infektion, Entzündung und Blutgerinnung. Basel , Grenzach-Wyhlen, Editiones “Roche”, 1990; 3–17.
- 40 Niederhoff H., Künzer W.. Physiologie der Hämostase der Neugeborenen. Monatsschr Kinderheilkd, 1985; 133: 130–6.
- 41 Zilliacus H., Ottelin AM. Blood clotting and fibrinolysis in human foetuses. Biol.. Neonat, 1966; 10: 108–12.
- 42 Ekelund H., Hedner U., Åstedt B.. Fibrinolysis in human foetuses. Acta Paediat Scand, 1970; 59: 369–76.
- 43 Åstedt B., Pandolfi M.. Ontogenesis of tissue plasminogen activator in humans. Thromb Diathes haemorrh, 1971; 25: 469–80.
- 44 Bleyer WA, Hakami N., Shepard Th. The development of hemostasis in the human fetus and newborn infant. J Pediatr, 1971; 79: 838–53.
- 45 Shigekiyo T., Uno Y., Tomonari A., Satoh K., Ueda S., Saito S.. Type I congenital plasminogen deficiency is not a risk factor for thrombosis. Thromb Haemostas, 1992; 67: 189–92.
- 46 Aoki N.. Genetic abnormalities of the fibrinolytic system. Semin Thromb Hemostas, 1984; 10: 42–50.
- 47 Schutta HS, Williams EC, Baranski BG, Sutula TP. Cerebral venous thrombosis with plasminogen deficiency. Stroke, 1991; 22: 401–5.
- 48 Tait RC, Walker ID, Conkie JA, Islam SIAM, McCall F.. Isolated familiar plasminogen deficiency may not be a risk factor for thrombosis. Thromb Haemost, 1996; 76(6): 1004–8.
- 49 Schott D., Dempfle C-E, Beck P., Liermann A., Mohr-Pennert A., Goldner M., Mehlem P., Azuma H., Schuster V., Mingers A-M, Schwarz HP, Kramer MD. Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency. New Engl J Med, 1998; 339: 1679–86.